Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

489

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Carcinoma
Interventions
PROCEDURE

Upfront cytoreductive surgery

Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5

PROCEDURE

Interval debulking surgery

3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy

Trial Locations (8)

200032

Zhongshan Hospital Fudan University, Shanghai

200040

Shanghai First Maternity and Infant Hospital Affiliated to Tongji University, Shanghai

200092

Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

310022

Zhejiang Cancer Hospital, Hangzhou

510060

Sun Yet-Sen University Cancer Center, Guangzhou

Unknown

Hunan Provincial Hospital, Changsha

Seoul National University Hospital, Seoul

Ajou University Hospital, Suwon

All Listed Sponsors
lead

Shanghai Gynecologic Oncology Group

OTHER_GOV